Key regions: France, India, United Kingdom, South Korea, Japan
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. It is characterized by inflammation, scarring, and loss of nerve cells, which can lead to a range of physical and cognitive symptoms. The market for MS drugs in Northern Africa has been developing in recent years, driven by a combination of factors.
Customer preferences: Patients with MS in Northern Africa tend to prefer oral medications over injectables, as they are more convenient and less painful. However, the availability of oral MS drugs in the region is limited, and many patients still rely on injectables. Cost is also a major consideration for patients, as MS drugs can be expensive and not always covered by insurance.
Trends in the market: The market for MS drugs in Northern Africa is growing, driven by increasing awareness of the disease and improved access to healthcare. However, the market is still relatively small compared to other regions, and there is significant room for growth. One trend that is driving growth in the market is the introduction of new drugs that offer improved efficacy and fewer side effects. Another trend is the increasing use of biosimilars, which are cheaper versions of existing MS drugs.
Local special circumstances: There are several factors that are unique to the MS market in Northern Africa. One is the relatively low prevalence of the disease compared to other regions. This means that there is less competition among drug manufacturers, and prices can be higher. Another factor is the lack of infrastructure in some countries, which can make it difficult to distribute and administer MS drugs.
Underlying macroeconomic factors: The MS market in Northern Africa is influenced by a range of macroeconomic factors, including economic growth, healthcare spending, and government policies. Economic growth is driving demand for healthcare services in the region, including MS drugs. Healthcare spending is also increasing, as governments invest in improving healthcare infrastructure and expanding access to care. Government policies can also have a significant impact on the MS market, particularly in terms of drug pricing and reimbursement. Overall, the MS market in Northern Africa is expected to continue growing in the coming years, driven by these and other factors.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
